Top

Published in:

Open Access 01-12-2008 | Research article

Expression of centromere protein F (CENP-F) associated with higher FDG uptake on PET/CT, detected by cDNA microarray, predicts high-risk patients with primary breast cancer

Authors: Shigeto Ueda, Nobuo Kondoh, Hitoshi Tsuda, Souhei Yamamoto, Hideki Asakawa, Kazuhiko Fukatsu, Takayuki Kobayashi, Junji Yamamoto, Katsumi Tamura, Jiro Ishida, Yoshiyuki Abe, Mikio Yamamoto, Hidetaka Mochizuki

Published in: BMC Cancer | Issue 1/2008

Abstract

Background

Higher standardized uptake value (SUV) detected by 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) correlates with proliferation of primary breast cancer. The purpose of this study is to identify specific molecules upregulated in primary breast cancers with a high SUV and to examine their clinical significance.

Methods

We compared mRNA expression profiles between 14 tumors with low SUVs and 24 tumors with high SUVs by cDNA microarray. We identified centromere protein F (CENP-F) and CDC6 were upregulated in tumors with high SUVs. RT-PCR and immunohistochemical analyses were performed to validate these data. Clinical implication of CENP-F and CDC6 was examined for 253 archival breast cancers by the tissue microarray.

Results

The relative ratios of CENP-F and CDC6 expression levels to β-actin were confirmed to be significantly higher in high SUV tumors than in low SUV tumors (p = 0.027 and 0.025, respectively) by RT-PCR. In immunohistochemical analysis of 47 node-negative tumors, the CENP-F expression was significantly higher in the high SUV tumors (74%) than the low SUV tumors (45%) (p = 0.04), but membranous and cytoplasmic CDC6 expressions did not significantly differ between both groups (p = 0.9 each). By the tissue microarray, CENP-F (HR = 2.94) as well as tumor size (HR = 4.49), nodal positivity (HR = 4.1), and Ki67 (HR = 2.05) showed independent impact on the patients' prognosis.

Conclusion

High CENP-F expression, correlated with high SUV, was the prognostic indicators of primary breast cancer. Tumoral SUV levels may serve as a pretherapeutic indicator of aggressiveness of breast cancer.

Available only for authorised users

Rauschecker H, Clarke M, Gatzemeier W, Recht A: Systemic therapy for treating locoregional recurrence in women with breast cancer. Cochrane Database Syst Rev. 2001, CD002195-4

Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ: Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol. 2007, 18 (7): 1133-1144. 10.1093/annonc/mdm271.CrossRefPubMed

Charlson ME, Feinstein AR: Rate of disease progression in breast cancer: a clinical estimate of prognosis within nodal and anatomic stages. J Natl Cancer Inst. 1984, 72 (2): 225-231.PubMed

Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004, 351 (27): 2817-2826. 10.1056/NEJMoa041588.CrossRefPubMed

van't Veer LJ, Dai H, Vijver van de MJ, He YD, Hart AA, Mao M, Peterse HL, Kooy van der K, Marton MJ, Witteveen AT, et al: Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002, 415 (6871): 530-536. 10.1038/415530a.CrossRef

Perreard L, Fan C, Quackenbush JF, Mullins M, Gauthier NP, Nelson E, Mone M, Hansen H, Buys SS, Rasmussen K, et al: Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay. Breast Cancer Res. 2006, 8 (2): R23-10.1186/bcr1399.CrossRefPubMedPubMedCentral

Juweid ME, Cheson BD: Positron-emission tomography and assessment of cancer therapy. N Engl J Med. 2006, 354 (5): 496-507. 10.1056/NEJMra050276.CrossRefPubMed

Weber WA, Ziegler SI, Thodtmann R, Hanauske AR, Schwaiger M: Reproducibility of metabolic measurements in malignant tumors using FDG PET. J Nucl Med. 1999, 40 (11): 1771-1777.PubMed

Ueda S, Tsuda H, Asakawa H, Shigekawa T, Fukatsu K, Kondo N, Yamamoto M, Hama Y, Tamura K, Ishida J, et al: Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer. Jpn J Clin Oncol. 2008, 38 (4): 250-258. 10.1093/jjco/hyn019.CrossRefPubMed

10.

Higashi K, Ueda Y, Arisaka Y, Sakuma T, Nambu Y, Oguchi M, Seki H, Taki S, Tonami H, Yamamoto I: 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer. J Nucl Med. 2002, 43 (1): 39-45.PubMed

11.

Vesselle H, Schmidt RA, Pugsley JM, Li M, Kohlmyer SG, Vallires E, Wood DE: Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res. 2000, 6 (10): 3837-3844.PubMed

12.

Nakamoto Y, Saga T, Fujii S: Positron emission tomography application for gynecologic tumors. Int J Gynecol Cancer. 2005, 15 (5): 701-709. 10.1111/j.1525-1438.2005.00245.x.CrossRefPubMed

13.

Buck A, Schirrmeister H, Kuhn T, Shen C, Kalker T, Kotzerke J, Dankerl A, Glatting G, Reske S, Mattfeldt T: FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. Eur J Nucl Med Mol Imaging. 2002, 29 (10): 1317-1323. 10.1007/s00259-002-0880-8.CrossRefPubMed

14.

Arai M, Kondoh N, Imazeki N, Hada A, Hatsuse K, Kimura F, Matsubara O, Mori K, Wakatsuki T, Yamamoto M: Transformation-associated gene regulation by ATF6alpha during hepatocarcinogenesis. FEBS Lett. 2006, 580 (1): 184-190. 10.1016/j.febslet.2005.11.072.CrossRefPubMed

15.

Kondoh N, Ohkura S, Arai M, Hada A, Ishikawa T, Yamazaki Y, Shindoh M, Takahashi M, Kitagawa Y, Matsubara O, et al: Gene expression signatures that can discriminate oral leukoplakia subtypes and squamous cell carcinoma. Oral Oncol. 2007, 43 (5): 455-462. 10.1016/j.oraloncology.2006.04.012.CrossRefPubMed

16.

Ueda S, Tsuda H, Sato K, Takeuchi H, Shigekawa T, Matsubara O, Hiraide H, Mochizuki H: Alternative tyrosine phosphorylation of signaling kinases according to hormone receptor status in breast cancer overexpressing the insulin-like growth factor receptor type 1. Cancer Sci. 2006, 97 (7): 597-604. 10.1111/j.1349-7006.2006.00228.x.CrossRefPubMed

17.

Iwaya K, Tsuda H, Hiraide H, Tamaki K, Tamakuma S, Fukutomi T, Mukai K, Hirohashi S: Nuclear p53 immunoreaction associated with poor prognosis of breast cancer. Jpn J Cancer Res. 1991, 82 (7): 835-840.CrossRefPubMed

18.

Buck AK, Schirrmeister H, Mattfeldt T, Reske SN: Biological characterisation of breast cancer by means of PET. Eur J Nucl Med Mol Imaging. 2004, 31 (Suppl 1): S80-87. 10.1007/s00259-004-1529-6.CrossRefPubMed

19.

Bos R, Hoeven van Der JJ, Wall van Der E, Groep van Der P, van Diest PJ, Comans EF, Joshi U, Semenza GL, Hoekstra OS, Lammertsma AA, et al: Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol. 2002, 20 (2): 379-387. 10.1200/JCO.20.2.379.CrossRefPubMed

20.

Avril N, Menzel M, Dose J, Schelling M, Weber W, Janicke F, Nathrath W, Schwaiger M: Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med. 2001, 42 (1): 9-16.PubMed

21.

Liao H, Winkfein RJ, Mack G, Rattner JB, Yen TJ: CENP-F is a protein of the nuclear matrix that assembles onto kinetochores at late G2 and is rapidly degraded after mitosis. J Cell Biol. 1995, 130 (3): 507-518. 10.1083/jcb.130.3.507.CrossRefPubMed

22.

O'Brien SL, Fagan A, Fox EJ, Millikan RC, Culhane AC, Brennan DJ, McCann AH, Hegarty S, Moyna S, Duffy MJ, et al: CENP-F expression is associated with poor prognosis and chromosomal instability in patients with primary breast cancer. Int J Cancer. 2007, 120 (7): 1434-1443. 10.1002/ijc.22413.CrossRefPubMed

23.

Hall JR, Kow E, Nevis KR, Lu CK, Luce KS, Zhong Q, Cook JG: Cdc6 stability is regulated by the Huwe1 ubiquitin ligase after DNA damage. Mol Biol Cell. 2007, 18 (9): 3340-3350. 10.1091/mbc.E07-02-0173.CrossRefPubMedPubMedCentral

24.

Duursma A, Agami R: p53-Dependent regulation of Cdc6 protein stability controls cellular proliferation. Mol Cell Biol. 2005, 25 (16): 6937-6947. 10.1128/MCB.25.16.6937-6947.2005.CrossRefPubMedPubMedCentral

25.

Fujita M, Yamada C, Goto H, Yokoyama N, Kuzushima K, Inagaki M, Tsurumi T: Cell cycle regulation of human CDC6 protein. Intracellular localization, interaction with the human mcm complex, and CDC2 kinase-mediated hyperphosphorylation. J Biol Chem. 1999, 274 (36): 25927-25932. 10.1074/jbc.274.36.25927.CrossRefPubMed

26.

Clay-Farrace L, Pelizon C, Santamaria D, Pines J, Laskey RA: Human replication protein Cdc6 prevents mitosis through a checkpoint mechanism that implicates Chk1. Embo J. 2003, 22 (3): 704-712. 10.1093/emboj/cdg046.CrossRefPubMedPubMedCentral

27.

Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC: American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007, 25 (33): 5287-5312. 10.1200/JCO.2007.14.2364.CrossRefPubMed

28.

Clark GM, Allred DC, Hilsenbeck SG, Chamness GC, Osborne CK, Jones D, Lee WH: Mitosin (a new proliferation marker) correlates with clinical outcome in node-negative breast cancer. Cancer Res. 1997, 57 (24): 5505-5508.PubMed

29.

Ohta S, Koide M, Tokuyama T, Yokota N, Nishizawa S, Namba H: Cdc6 expression as a marker of proliferative activity in brain tumors. Oncol Rep. 2001, 8 (5): 1063-1066.PubMed

30.

Murphy N, Ring M, Heffron CC, King B, Killalea AG, Hughes C, Martin CM, McGuinness E, Sheils O, O'Leary JJ: p16INK4A, CDC6, and MCM5: predictive biomarkers in cervical preinvasive neoplasia and cervical cancer. J Clin Pathol. 2005, 58 (5): 525-534. 10.1136/jcp.2004.018895.CrossRefPubMedPubMedCentral

31.

Tsuda H, Iwaya K, Fukutomi T, Hirohashi S: p53 mutations and c-erbB-2 amplification in intraductal and invasive breast carcinomas of high histologic grade. Jpn J Cancer Res. 1993, 84 (4): 394-401.CrossRefPubMed

32.

Tsuda H, Hirohashi S: Association among p53 gene mutation, nuclear accumulation of the p53 protein and aggressive phenotypes in breast cancer. Int J Cancer. 1994, 57 (4): 498-503. 10.1002/ijc.2910570410.CrossRefPubMed

The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/8/384/prepub

Title: Expression of centromere protein F (CENP-F) associated with higher FDG uptake on PET/CT, detected by cDNA microarray, predicts high-risk patients with primary breast cancer
Authors: Shigeto Ueda
Nobuo Kondoh
Hitoshi Tsuda
Souhei Yamamoto
Hideki Asakawa
Kazuhiko Fukatsu
Takayuki Kobayashi
Junji Yamamoto
Katsumi Tamura
Jiro Ishida
Yoshiyuki Abe
Mikio Yamamoto
Hidetaka Mochizuki
Publication date: 01-12-2008
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2008
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/1471-2407-8-384

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2008

Carbonic anhydrase IX in oligodendroglial brain tumors

Human pregnane X receptor is expressed in breast carcinomas, potential heterodimers formation between hPXR and RXR-alpha

Expression profile of CREB knockdown in myeloid leukemia cells

Expression of hepcidin mRNA is uniformly suppressed in hepatocellular carcinoma

A haplotype of polymorphisms in ASE-1, RAI and ERCC1and the effects of tobacco smoking and alcohol consumption on risk of colorectal cancer: a danish prospective case-cohort study

SOCS3 inhibiting migration of A549 cells correlates with PYK2 signaling in vitro

Keynote webinar | Spotlight on antibody–drug conjugates in cancer